^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gallbladder Cancer

    Related cancers:
    2d
    Clinicopathological and Radiological Profile of Gallbladder Carcinoma: A Cross-Sectional Study From a Tertiary Care Center in Tripura, India. (PubMed, Cureus)
    Conclusion Gallbladder carcinoma patients in Tripura predominantly present with advanced-stage disease and exhibit a strong female preponderance. The high burden of locoregional and metastatic spread underscores the need for region-specific awareness, earlier diagnostic strategies, and strengthened referral pathways to improve outcomes in this high-risk population.
    Observational data • Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    5d
    Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov)
    P1, N=48, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • emavusertib (CA-4948)
    5d
    GPX3 suppresses gallbladder cancer progression by modulating redox balance, glycolysis, and anti-tumor immunity. (PubMed, Oncogenesis)
    These findings identify GPX3 as a critical tumor suppressor that integrates redox regulation, metabolic reprogramming, and immune activation to restrict malignant progression. Targeting GPX3 or its downstream pathways may represent a promising therapeutic strategy to simultaneously suppress gallbladder cancer aggressiveness and reinforce anti-tumor immunity.
    Journal
    |
    CD8 (cluster of differentiation 8) • GPX3 (Glutathione Peroxidase 3)
    5d
    EAY191-A6: Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Oct 2026 | Trial primary completion date: May 2026 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    MAPK1 (Mitogen-activated protein kinase 1)
    |
    BRAF V600E • BRAF V600
    |
    Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical
    7d
    Oncogenic GPRIN1 sustains proliferation and mitochondrial homeostasis via dual‑layer CDK1-PI3K/Akt signalling in gallbladder cancer. (PubMed, Cell Death Dis)
    Importantly, genetic or pharmacological disruption of this GPRIN1-CDK1-PI3K/Akt axis completely abrogated tumorigenesis in vitro and in vivo. Taken together, these results reveal GPRIN1 as a master regulator whose dual transcriptional and post-translational control of CDK1 integrates cell cycle progression with mitochondrial homeostasis, suggesting that targeting GPRIN1 may represent a highly specific therapeutic strategy in this lethal malignancy.
    Clinical • Observational data • Retrospective data • Review • Journal
    |
    CDC25C (Cell Division Cycle 25C) • CDK1 (Cyclin-dependent kinase 1) • PKMYT1 (Protein Kinase Membrane Associated Tyrosine/Threonine 1) • E2F1 (E2F transcription factor 1) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
    7d
    Global patterns of mutational profiles in biliary tract cancer. (PubMed, J Hepatol)
    This cross-study integrative analysis provides an international view of BTC genomics, codifying how geography, etiology, and anatomical subtype together shape driver landscapes.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • BAP1 (BRCA1 Associated Protein 1)
    7d
    Primary gallbladder carcinomas showing pancreatic acinar features in the absence of a pancreatic primary. (PubMed, Histopathology)
    Gallbladder carcinomas may rarely exhibit acinar differentiation that closely mirrors pancreatic ACC. Recognition of this phenotype expands the morphologic repertoire of gallbladder carcinomas.
    Journal
    |
    TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1)
    |
    TP53 mutation
    9d
    Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers (clinicaltrials.gov)
    P1/2, N=31, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2026 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    Fotivda (tivozanib)
    10d
    AB02: A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) (clinicaltrials.gov)
    P3, N=186, Recruiting, AstraZeneca | N=89 --> 186
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • rilvegostomig (AZD2936)
    11d
    TRAP-BTC: Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting --> Active, not recruiting | Trial completion date: Apr 2028 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin
    12d
    Prognostic Value of Combined Carbohydrate Antigen 19-9 and Duke Pancreatic Monoclonal Antigen Type 2 Assessment in Biliary Tract Cancer. (PubMed, Ann Surg Oncol)
    Concurrent normal CA19-9 and DUPAN-2 levels independently predicted favorable outcomes. Combined preoperative biomarker assessment may contribute to prognostic stratification of BTCs, including among patients with Lewis antigen negativity or impaired FUT3 function.
    Journal
    |
    FUT3 (Fucosyltransferase 3) • CA 19-9 (Cancer antigen 19-9)
    13d
    TOURMALINE: Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (clinicaltrials.gov)
    P3, N=142, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2026 --> Sep 2026
    Trial completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)